SHH and metabolic dysfunction-associated steatohepatitis: During the NIDDK-sponsored PIVENS trial (NCT00063622), treatment response paralleled to loss of Shh+ hepatocytes and improvement in Hh-regulated processes that promote NASH progression, indicating that VitE treatment and improvement in NASH were associated with changes in Hh signaling activity [107].